- Preparation method of piperazine ethanesulfonic acid derivative (by machine translation)
-
The reaction is carried out in such a manner that the reaction proceeds relatively, more thoroughly by reducing the side, reaction of the reaction system, in a manner such that the reaction proceeds relatively more thoroughly from, the system to 2 - a certain extent 2 - by reducing the reaction proceeds, to relatively more thoroughly; NaOH, NaCl, and. (by machine translation)
- -
-
Paragraph 0048-0087
(2020/02/06)
-
- High purity 4 - hydroxyethyl piperazine b sulfonic acid
-
The invention belongs to the technical field of organic matter preparation, and particularly relates to a method for preparing high-purity 4-hydroxyethyl piperazine ethane sulfonic acid. The method comprises the following steps: carrying out addition reaction on vinylsulfonic acid or vinyl sulfonate and N-hydroxyethyl piperazine to prepare 4-hydroxyethylpiperazine ethane sulfonate; converting the 4-hydroxyethylpiperazine ethane sulfonate into 4-hydroxyethylpiperazine ethane sulfonic acid and corresponding salts of an acidifier by adopting the acidifier, thus obtaining acidifying mother liquor; then crystallizing to remove the corresponding salts of the acidifier to obtain processed acidifying mother liquor; adding soluble barium salt or calcium salt to the processed acidifying mother liquor to remove residual sulfate radicals, and carrying out evaporative concentration to obtain a primary purified product of the 4-hydroxyethylpiperazine ethane sulfonic acid; finally, washing the primary purified product by adopting small molecular weight alcohol and drying to obtain the high-purity 4-hydroxyethylpiperazine ethane sulfonic acid. The 4-hydroxyethylpiperazine ethane sulfonic acid prepared by the method disclosed by the invention is high in purity, simple and convenient in operation process, environment-friendly in production process, low in purification cost, high in yield and suitable for industrial batch production.
- -
-
Paragraph 0051; 0052; 0060; 0061
(2017/09/26)
-
- Method for preparing high-purity 4-hydroxyethylpiperazine ethanesulfonic acid
-
The invention belongs to the technical field of preparation of organic matters, and relates to a method for preparing high-purity 4-hydroxyethylpiperazine ethanesulfonic acid. The method sequentially comprises the following specific steps: preparation of 4-hydroxyethylpiperazine ethanesulfonate, acidizing, extraction for decolorizing and removing impurities, reverse extraction, nanofiltration and washing, and drying, so that the high-purity 4-hydroxyethylpiperazine ethanesulfonic acid is finally obtained. The 4-hydroxyethylpiperazine ethanesulfonic acid prepared with the method provided by the invention is high in purity; the operation process is simple and convenient; the production process is environmentally friendly; the purification cost is low; the yield is high; the method is suitable for industrial batch production.
- -
-
Paragraph 0034; 0035; 0047
(2017/07/19)
-
- COAGULATION FACTOR VII POLYPEPTIDES
-
The present invention relates to modified coagulation Factor VII polypeptides exhibiting increased resistance to antithrombin inactivation and enhanced proteolytic activity. The present invention also relates to polynucleotide constructs encoding such polypeptides, vectors and host cells comprising and expressing such polynucleotides, pharmaceutical compositions, uses and methods of treatment.
- -
-
Page/Page column
(2015/04/21)
-
- Peptides for Treatment of Obesity
-
The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.
- -
-
-
- Stabilizing labeled antibody using amino acids
-
The present invention relates to a method for stabilizing a labeled antibody in a solution, in which the labeled antibody is stabilized by allowing the labeled antibody to be present together with at least one of amino acid and a derivative thereof in the solution.
- -
-
-
- Isolation of nucleic acids
-
A method for extracting nucleic acids from a biological material such as blood comprises contacting the mixture with a material at a pH such that the material is positively charged and will bind negatively charged nucleic acids and then eluting the nucleic acids at a pH when the said materials possess a neutral or negative charge to release the nucleic acids. The nucleic acids can be removed under mildly alkaline conditions to the maintain integrity of the nucleic acids and to allow retrieval of the nucleic acids in reagents that are immediately compatible with either storage or analytical testing.
- -
-
-
- Zwitterionic compounds and their n-halo derivatives for use in the treatment of clinical conditions
-
Zwitterionic compounds selected from: taurine (2-aminoethanesulphonic acid), 2(N-morpholino)ethanesulphonic acid (MES), N-(2-acetamido)iminodiacetic acid (ADA), piperazine-N,N'bis(2-ethanesulphonic acid (PIPES), N-(2-acetamido)-2-aminoethanesulphonic acid (ACES), N,N-bis(2-hydroxyethyl)-2-aminoethanesulphonic acid (BES), 3-(N-morpholino)propanesulphonic (MOPS), N-N[tris(hydroxymethyl)-methyl]-2-aminoethanesulphonic acid (TES), N-2-hydroxyethylpiperazine-N'-2-ethanesulphonic acid (HEPES), N-2-hydroxyethylpiperazine-N'3-propanesulphonic acid (H)EPPS), 2-(cyclohexylamino)ethanesulphonic acid (CHES) or 3-(cyclohexylamino)propanesulphonic acid (CAPS), and their N-halo derivatives can be used separately or in combination in the treatment of related clinical conditions by stimulating myeloperoxidase activity, which in turn stimulates hypochlorous acid production in vivo, which leads inter alia to enhanced leukotriene inactivation.
- -
-
-
- Use of zwitterionic compounds and their N-halo derivatives
-
Zwitterionic compounds selected from:, taurine (2-aminoethanesulphonic acid), 2(N-morpholino)ethanesulphonic acid (MES), N-(2-acetamido) iminodiacetic acid (ADA), piperazine-N,N?bis(2-ethanesulphonic acid (PIPES), N-(2-acetamido)-2-aminoethanesulphonic acid (ACES), N,N-bis(2-hydroxyethyl)-2-aminoethanesulphonic acid (BES), 3-(N-morpholino)propanesulphonic (MOPS), N-N[tris(hydroxymethyl)-methyl]-2-aminoethanesulphonic acid (TES), N-2-hydroxyethylpiperazine-N?-2-ethanesulphonic acid (HEPES), N-2-hydroxyethylpiperazine-N?3-propanesulphonic acid ((H)EPPS), 2-(cyclohexylamino) ethanesulphonic acid (CHES) or 3-(cyclohexylamino) propanesulphonic acid (CAPS), and their N-halo derivatives can be used separately or in combination in the treatment of related clinical conditions by stimulating myeloperoxidase activity, which in turn stimulates hypochlorous acid production in vivo, which leads inter aliato enhanced leukotriene inactivation.
- -
-
-
